Viewing
News|Articles|September 29, 2026

Back where the IOL began: Highlights from ESCRS 2026

Key takeaways on IOLs, glaucoma lasers, ocular pain and AI in London

Cataract and refractive surgeons returned to the city where the first intraocular lens (IOL) was implanted for the 44th Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), held 11–15 September 2026 at ExCeL London.

Clinicians shared practical takeaways in their sessions and in interviews with Ophthalmology Times Europe, from IOL selection and laser-based glaucoma procedures to ocular pain that resists dry eye therapy and the growing role of artificial intelligence (AI). In case you missed it, here are highlights from our ESCRS 2026 coverage.

>>> See all of our ESCRS 2026 coverage.

Cataract and IOLs

Jascha Wendelstein, MD, of the IROC Institute in Zurich, Switzerland, argued that standard letter charts may be too blunt to separate multifocal IOLs. In his comparison of three diffractive lenses, distance-corrected visual acuity was similar, but reading speed fell from roughly 130–140 words per minute in photopic light to about 30 under mesopic conditions—well below the 80 words per minute generally considered satisfying. He considers reading speed the best current proxy for functional vision and advised surgeons to benchmark any new lens against their own defocus curves and outcomes.

Mfazo Hove, MD, FRCOphth, a London-based consultant ophthalmologist who has lived with a trifocal IOL for 2.5 years, told Ophthalmology Times Europe that surgeons should be willing to have the premium treatments they offer. “If you don’t believe in it, or trust it enough to have it in your own eyes, then the question you should be asking yourself is why you’d give it to your patients,” he said.

Glaucoma

Zoltan Z. Nagy, MD, PhD, FEBO, FACS, of Semmelweis University in Budapest, Hungary, presented 48-month outcomes for femtosecond laser image-guided high-precision trabeculotomy (FLigHT), a non-incisional procedure for open-angle glaucoma. Mean intraocular pressure (IOP) fell 27%, from 21.4 mmHg to a stable 14.9 mmHg, with no fibrosis or occlusion of the laser-created channels on optical coherence tomography.

Cathleen McCabe, MD, of The Eye Associates in Bradenton and Sarasota, Florida, US, presented 2-year results for implant-free excimer laser trabeculostomy (ELIOS; Bausch + Lomb) in 318 patients with mild to moderate glaucoma. Mean IOP fell by more than 8 mmHg, and medication-free rates held at 86% at 12 months and 84% at 2 years.

Ocular surface

Anat Galor, MD, MSPH, of the Miami VA Healthcare System and Bascom Palmer Eye Institute, US, cautioned that persistent, severe ocular pain is not always undertreated dry eye. Her patient, a 50-year-old woman with Sjögren’s disease, reported constant pain rated 9 out of 10 despite years of therapy, yet her ocular surface findings could not explain that severity. Clues to somatosensory dysfunction include burning triggered by wind and light, abnormal corneal sensitivity and pain that persists after topical anaesthetic, Galor said. Her advice was to treat the mechanism, not just the label.

Giuseppe Giannaccare, MD, PhD, FEBOphth, of the University of Cagliari, Italy, presented a randomized, sham-controlled trial of low-level light therapy delivered 1 week before and 1 week after cataract surgery. Patients who received light therapy showed significantly greater clinical improvement than sham-treated controls (44.2% vs 4.4%; P < .0001).

Refractive surgery and presbyopia

Robert Ang, MD, of the Asian Eye Institute in the Philippines, presented 3-year contralateral-eye data showing single-step trans-epithelial photorefractive keratectomy (TransPRK) matched conventional alcohol-assisted PRK. About 96% of eyes in each arm achieved 20/20 uncorrected distance vision, and healing time and pain were equivalent.

Maria Soledad Romero, MD, of Precision Eye Care in Baltimore, presented real-world data on aceclidine ophthalmic solution 1.44% (VIZZ; LENZ Therapeutics) for presbyopia. Patients noticed improved near vision within 15–30 minutes, but only 9 of 61 (14.8%) remained on treatment at 3 months, a drop-off she attributed mainly to cost and insufficient patient education.

Myopia

Mark Bullimore, PhD, MCOptom, of the University of Houston, shared early randomized trial data on a second-generation myopia control spectacle lens (Stellest 2.0; Essilor). Slowing of progression that took 12 months with the original lens was seen within 6 months, suggesting the new design may be roughly twice as effective.

He also argued that delaying myopia onset by even 1 year can be worth 2–3 years of slowed progression, and urged clinicians to identify at-risk children rather than treat every child.

Artificial intelligence

AI was a recurring thread. Ana Miguel, MD, PhD, FEBO, FEBO-G, GCSRT, an ophthalmologist practising in France, said AI outperformed a group of European glaucoma experts in her team’s study but still needs human validation “as a second check.” Adam Muzychuk, MD, BSc, FRCSC, of the University of Calgary, Canada, warned that “what gives you the best numbers mathematically may not always be what’s best for the patient.”

Jai Parekh, MD, MA, FAAO, an anterior segment surgeon in New Jersey, US, was optimistic. “It’s going to be disruptive in an innovative way, and it’s going to make us all better,” he said.


Related to this article